Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cardiol Therapeutics Inc. is a Canada-based clinical-stage biotechnology company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company operates within the biopharmaceutical and cardiovascular therapeutics industries, with a strategic emphasis on inflammatory cardiac conditions that currently have limited approved treatment options. Its primary product candidate portfolio includes proprietary pharmaceutical cannabidiol formulations designed for conditions such as recurrent pericarditis, myocarditis, and heart failure. The company’s revenue generation has historically been limited because it remains in the clinical development stage and has not commercialized approved therapies as of publicly available filings through 2025.
The company’s lead clinical asset is CardiolRx™, an orally administered cannabidiol formulation under investigation for inflammatory heart disease indications. Cardiol Therapeutics has also advanced subcutaneous drug delivery initiatives through its CRD-38 program. The company positions itself around pharmaceutical-grade cannabidiol manufacturing standards, intellectual property development, and targeted cardiovascular applications, distinguishing itself from broader cannabinoid-focused companies that operate in consumer wellness or recreational markets. Founded in 2017, the company evolved from early-stage cannabinoid pharmaceutical development into a specialized cardiovascular therapeutics developer listed on both the Nasdaq Capital Market and the Toronto Stock Exchange.
Business Operations
Cardiol Therapeutics primarily operates through a single biotechnology development platform focused on cardiovascular inflammation and fibrosis. Its operations include clinical research, regulatory engagement, drug formulation development, intellectual property management, and outsourced manufacturing partnerships. The company’s core business activities are centered on advancing CardiolRx™ through clinical trials, including studies involving recurrent pericarditis and myocarditis. Research and development expenditures represent the company’s primary operational use of capital according to publicly available filings, including disclosures in SEC filings and annual reports.
The company conducts operations across Canada and the United States, with clinical trial activity extending into additional international jurisdictions depending on study requirements. Cardiol Therapeutics relies on third-party contract research organizations, manufacturing partners, and clinical investigators to support development activities rather than maintaining large-scale in-house manufacturing infrastructure. The company also maintains proprietary formulation technologies and intellectual property associated with pharmaceutical cannabidiol production and delivery. Public disclosures do not indicate material revenue-generating subsidiaries or large-scale joint ventures as of the latest available reporting period.
Strategic Position & Investments
Cardiol Therapeutics’ strategic direction centers on becoming a specialized cardiovascular therapeutics company targeting inflammatory and fibrotic heart disease. Its growth initiatives focus on advancing late-stage clinical development, expanding intellectual property protections, strengthening regulatory positioning, and evaluating broader applications of cannabidiol-based therapeutics in cardiovascular medicine. The company has emphasized clinical differentiation through pharmaceutical-grade purity standards and disease-specific therapeutic targeting rather than generalized cannabinoid commercialization.
The company has invested significantly in clinical trials, manufacturing process development, and formulation technologies tied to CardiolRx™ and CRD-38. Strategic efforts have included expanding patent portfolios and advancing clinical collaborations with cardiovascular research institutions. Publicly available information does not indicate major transformative acquisitions comparable to larger pharmaceutical sector transactions. Data regarding significant portfolio-company investments or material equity stakes in unrelated businesses is inconclusive based on available public sources.
Geographic Footprint
Cardiol Therapeutics is headquartered in Oakville, Ontario, Canada, and maintains a North American operational focus with clinical development activities extending internationally through multicenter trial participation. The company’s securities trade on both the Nasdaq Capital Market in the United States and the Toronto Stock Exchange in Canada, providing access to both U.S. and Canadian capital markets.
Its operational footprint primarily spans North America, although clinical research collaborations and trial sites may include institutions in additional global regions depending on regulatory approvals and study design. The company’s market visibility is strongest among biotechnology investors, cardiovascular research institutions, and specialty pharmaceutical stakeholders in the United States and Canada. Public filings do not identify substantial commercial operations in Europe, Asia-Pacific, or Latin America because the company remains in the clinical development stage rather than commercial distribution.
Leadership & Governance
Cardiol Therapeutics is led by executives with backgrounds in biotechnology, pharmaceuticals, finance, and cardiovascular-focused commercialization. The company’s governance structure follows public-company standards applicable to issuers listed in both Canada and the United States. Leadership has consistently emphasized disciplined clinical development, regulatory rigor, and the pursuit of therapies for underserved cardiovascular inflammatory diseases.
Key executives and leadership personnel include:
- David Elsley – President and Chief Executive Officer
- Andrew Hamer – Chief Financial Officer
- Guillaume Charron – Chief Operating Officer
- Dr. Andrew Yan – Chief Medical Advisor
- Dr. Eldon Smith – Chair of the Board
Company leadership has publicly communicated a strategy centered on advancing evidence-based cardiovascular therapeutics through clinical validation and targeted regulatory pathways. Governance practices and executive responsibilities are disclosed through SEC filings, annual information forms, and investor materials.